Hepatic extraction, metabolism, and biliary excretion of irinotecan in the isolated perfused rat liver

Journal of Pharmaceutical Sciences

Volumn 90, Issue 6, 2001, Pages 722-731

  Farabos, Christian ^a   Haaz, Marie Christine ^a   Gires, Pierre ^b   Robert, Jacques ^a  

^a INSTITUT BERGONIÉ   (France)

^b Rhne Poulenc Rorer   (France)

Author keywords

Camptothecine; Drug metabolism; Irinotecan; Isolated perfused rat liver

Indexed keywords

7 ETHYL 10 HYDROXYCAMPTOTHECIN; DRUG METABOLITE; GLUCURONIDE; IRINOTECAN;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; BILIARY EXCRETION; BOLUS INJECTION; COLORECTAL CARCINOMA; CONTROLLED STUDY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG HALF LIFE; DRUG ISOLATION; DRUG METABOLISM; ISOLATED LIVER; LIVER PERFUSION; MALE; NONHUMAN; RAT;

EID: 0034988420     PISSN: 00223549     EISSN: None     Source Type: Journal    
DOI: 10.1002/jps.1028     Document Type: Article

References (30)

1. Plant antitumor agents. I. The isolation and structure of camptothecin, a novel alkaloidal leukemia and tumor inhibitor from Camptotheca acuminata
2. Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer
3. Intracellular roles of SN-38, a metabolite of the camptothecin derivative CPT-11, in the anti-tumor effect of CPT-11
4. Identification of a β-glucuronide metabolite of SN-38 in human plasma after administration of the camptothecin derivative irinotecan
5. Identification and properties of a major plasma metabolite of irinotecan (CPT-11) isolated from the plasma of patients
6. Identification of a new metabolite of irinotecan (CPT-11). Pharmacological properties and activation to SN-38
7. Metabolism of irinotecan (CPT-11) by human hepatic microsomes. Participation of cytochrome P450 3A and drug interactions
8. Biosynthesis of an aminopiperidino metabolite of irinotecan by human hepatic microsomes
9. Bioactivation of the anticancer agent CPT-11 to SN-38 by human hepatic microsomal carboxylesterases and the in vitro assessment of potential drug interactions
10. Pharmacology of irinotecan
11. Reversed-phase high-performance liquid chromatographic method for the simultaneous quantitation of the carboxylate and lactone forms of the camptothecin derivative irinotecan, CPT-11, and its metabolite SN-38 in plasma
12. A physiological approach to hepatic drug clearance
13. Kinetic studies of the hydrolysis and lactonization of camptothecin and its derivatives, CPT-11 and SN-38, in aqueous solution
14. Kinetics of the in vivo interconversion of carboxylate and the lactone forms of irinotecan (CPT-11) and of its metabolite SN-38 in patients
15. The transformation of irinotecan (CPT-11) to its active metabolite SN-38 by human liver microsomes. Differential hydrolysis for the lactone and carboxylate forms
16. The role of rat serum carboxylesterase in the activation of paclitaxel and camptothecin prodrugs
17. Marked interspecies variations concerning the interactions of camptothecin with serum albumins: A frequency-domain fluorescence spectroscopy study
18. Pharmacokinetic interrelationships of irinotecan (CPT-11) and its three major plasma metabolites in patients enrolled in phase I/II trials
19. Population pharmacokinetics and pharmacodynamics of irinotecan (CPT-11) and active metabolite SN-38 during phase I trials
20. Nonlinear pharmacokinetics of CPT-11 in rats
21. Pharmacokinetic modulation of irinotecan and metabolites by cyclosporine A
22. Multispecific organic anion transporter is responsible for the biliary excretion of the camptothecin derivative irinotecan and its metabolites in rats
23. Glucuronidation of SN-38, the active metabolite of irinotecan, by human liver microsomes
24. Genetic predisposition to the metabolism of irinotecan (CPT-11). Role of uridine diphosphate glucuronosyl transferase isoform 1A1 in the glucuronidation of the active metabolite (SN-38) in human liver microsomes
25. Pharmacokinetics of irinotecan and its metabolites in human blood, bile, and urine
26. Identification of the metabolites of irinotecan, a new derivative of camptothecin, in rat bile and its biliary excretion
27. Multiplicity of biliary excretion mechanisms for irinotecan, CPT-11, and its metabolites in rats
28. Possible involvement of P-glycoprotein in biliary excretion of CPT-11 in rats
29. Pharmacokinetics of the 9-amino and 10-11-methylenedioxy derivatives of camptothecin in mice
30. Urinary and biliary disposition of the lactone and carboxylate forms of 20(S)-camptothecin in rats